›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoScreen™ Focus CDx Tissue Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Burning Rock BiotechType:
CE Marked
Related tests:
The OncoScreen™ Focus CDx Tissue Kit is a qualitative NGS-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of mutations in 13 genes including EGFR/ALK/ROS1/RET/MET/ERBB2/BRAF/PIK3CA/KRAS/NRAS/HRAS/KIT/PDGFRA using DNA extracted from FFPE tissues in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastrointestinal stromal tumor (GIST). Mutations include SNV, InDel, rearrangement (fusion), and CNV.
Cancer:
Colorectal Cancer, Gastrointestinal Stromal Tumor, Non Small Cell Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), KIT (KIT proto-oncogene, receptor tyrosine kinase)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
Method:
Next-Generation Sequencing (NGS)
Approvals
Date
Cancer
Gene
Biomarker
Drug
Approved by
